Cargando…
Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability
BACKGROUND: Chimeric antigen receptor-engineered T cell (CAR-T) therapy has shown promising potential for anti-cancer treatment. However, for pancreatic ductal adenocarcinoma (PDAC), the lack of infiltrative ability of these CAR-T cells leads to sub-optimal treatment outcome. METHODS: Chemokine (C-C...
Autores principales: | Hu, Jian-fei, Wang, Zu-wei, Liao, Cheng-yu, Chen, Zhi-wen, Kang, Feng-ping, Lin, Cai-feng, Lin, Tian-sheng, Huang, Long, Tian, Yi-feng, Chen, Shi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391072/ https://www.ncbi.nlm.nih.gov/pubmed/35990619 http://dx.doi.org/10.3389/fimmu.2022.958960 |
Ejemplares similares
-
The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma
por: Duan, Deming, et al.
Publicado: (2021) -
Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells
por: Feng, Jia, et al.
Publicado: (2022) -
Optimized Intracellular Staining Reveals Heterogeneous Cytokine Production Ability of Murine and Human Hematopoietic Stem and Progenitor Cells
por: Luo, Shufeng, et al.
Publicado: (2021) -
A humanized anti-human adenovirus 55 monoclonal antibody with good neutralization ability
por: Chen, Lei, et al.
Publicado: (2023) -
Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy
por: Das, Shipra, et al.
Publicado: (2023)